Predictive Oncology

What Predictive Oncology does

Predictive Oncology, now operating as Axe Compute Inc. (NASDAQ: AGPU, formerly POAI), is an AI-driven drug discovery and clinical testing company serving biopharmaceutical companies, academic researchers, and oncologists. The company's core offering is the PEDAL (Patient-centric Drug Discovery by Active Learning) platform, which pairs the CORE™ machine learning engine — exclusively licensed from Carnegie Mellon University — with a proprietary biobank of over 150,000 tumor samples spanning 137 cancer types. The platform demonstrates 92% accuracy in predicting drug-tumor pairings and uses an active learning approach that reportedly reduces wet-lab experiments to ~3% of possible combinations while maintaining high prediction confidence. Supporting offerings include zPREDICTA 3D tumor models, Soluble Biotech protein formulation services, and the CLIA-certified Helomics clinical lab providing ChemoFx drug-response and BioSpeciFx biomarker testing.

The company monetizes through professional services: AI-driven drug discovery engagements (quote-based, multi-year enterprise contracts), 3D tumor model development and screening, protein solubility/formulation services, and clinical lab testing (tumor drug-response profiling capped at $615 per patient, with biomarker tests covered by Medicare/most insurers). Distribution is enterprise field sales-led for biopharma, supplemented by the no-cost ACE academic program, clinical lab orders from clinicians, and channel partnerships with Cancer Research Horizons and Labcorp. Headcount is 11–50 with offices in Pittsburgh (HQ) and Eagan, MN.

In 2025 the company executed a material strategic pivot, completing a $343.5 million PIPE financing in October to establish a Strategic Compute Reserve of Aethir (ATH) tokens and repositioning itself as an enterprise GPU infrastructure provider via the Aethir decentralized network. The company rebranded to Axe Compute Inc. in December 2025, executed a 1-for-15 reverse split in September 2025 to maintain Nasdaq compliance, and added DNA Ventures leadership. As of Q2 2026 the company reported 20+ enterprise customers and 30+ live GPU deployments under an expected monthly contract value of $850,000, while FY2025 legacy drug discovery revenue remained at $125,284 and the company reported a $232.9 million FY2025 net loss driven primarily by non-cash digital asset fair-value adjustments.

Name

Predictive Oncology

Legal name

Predictive Oncology Inc.

Website

https://predictive-oncology.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Predictive Oncology (Axe Compute, NASDAQ: AGPU) is an AI-driven drug discovery company using its 150,000-sample tumor biobank and Carnegie Mellon–licensed CORE™ ML to predict drug-tumor responses for biopharma, academics, and clinicians. It recently pivoted into decentralized GPU compute infrastructure via Aethir.

Ownership category

akta.pro rank

Product category

AI-Driven Oncology Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

Keywords

• AI drug discovery
• Oncology biobank
• 3D tumor modeling
• Clinical biomarker testing
• Machine learning pharma

Headquarters

HQ city

Eagan

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Drug Discovery Services: AI-driven oncology services including the PEDAL platform for biopharma partners to predict drug-tumor pairings and improve probability of technical success in drug development.
2. Clinical Testing Services: Tumor drug-response testing (ChemoFx) and genomic biomarker testing (BioSpeciFx) through CLIA-certified Helomics Clinical Laboratory for clinicians and patients.
3. 3D Tumor Models: Organ-specific 3D cell culture models and services for pharmaceutical/biotech drug screening and development, including custom model development.
4. Solubility/Formulation Services: Protein solubility and stability formulation services through Soluble Biotech for pharmaceutical and biotech companies.
5. Vaccine Development Collaboration: Collaboration with FluGen on stable intranasal flu vaccine development supported by $6.2M Phase 2B grant from U.S. Department of Defense.
6. GPU Compute Infrastructure: Enterprise GPU infrastructure services through Aethir network for AI workloads, accessed via Strategic Compute Reserve of ATH tokens. New business segment launched September 2025, targeting enterprise customers in 2026.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Predictive Oncology develops and sells an AI/ML-driven drug discovery platform (PEDAL) that pairs a proprietary biobank of more than 150,000 tumor samples across 137 cancer types with an exclusively licensed Carnegie Mellon active-learning engine (CORE™) to predict drug-tumor responses, supplemented by 3D tumor models, CLIA-certified clinical testing (ChemoFx, BioSpeciFx), and protein formulation services (Soluble Biotech) for pharmaceutical and biotech customers. In late 2025 the company expanded into enterprise GPU compute infrastructure on the Aethir decentralized network as a parallel business line.

Product overview

Predictive Oncology operates a multi-product portfolio centered on AI-driven oncology drug discovery and clinical testing services. The core offering is the PEDAL platform, which combines proprietary machine learning (CORE™ engine from Carnegie Mellon) with a biobank of 150,000+ tumor samples to predict drug-tumor pairings with 92% accuracy. Supporting products include zPREDICTA 3D tumor models (r-Bone, r-Lung) for preclinical testing, the Helomics clinical laboratory offering ChemoFx drug-response testing and BioSpeciFx genomic biomarker analysis (CLIA-certified), and Soluble Biotech for protein formulation services. The ACE program provides academic researchers free access to the platform. Recent strategic expansion includes a digital asset treasury strategy and GPU compute infrastructure through the Aethir network partnership. The company rebranded to Axe Compute Inc. in late 2025 while maintaining its drug discovery operations.

Differentiator

Problem solved

Functional benefit

Brands

• Helomics: CLIA-certified clinical laboratory offering tumor drug-response testing (ChemoFx) and genomic biomarker testing services
• PEDAL
• zPREDICTA
• Soluble Biotech
• CORE
• STREAMWAY

Products and services

• PEDAL (Patient-centric Drug Discovery by Active Learning) AI/ML-driven drug discovery platform combining active machine learning with the company's proprietary biobank of 150,000+ tumor samples across 137 cancer types to predict drug-tumor pairings and accelerate oncology drug development for biopharma partners.
• 3D Tumor Models (zPREDICTA, including r-Bone and r-Lung) Human tumor and organ-specific in vitro 3D culture models, including r-Bone for bone marrow tissue and r-Lung for lung cancer, that mimic patient drug response with high correlation to clinical outcomes for pharmaceutical and biotech drug screening customers.
• ChemoFx (Tumor Drug-Response Testing) Live-cell tumor drug-response testing service that determines how a patient's tumor responds to various chemotherapy options, ordered by clinicians through the Helomics CLIA-certified clinical laboratory.
• BioSpeciFx (Genomic Biomarker Testing) Genomic biomarker testing panel that analyzes cancer-related genetic markers to predict treatment response and disease progression, covered by most insurers and Medicare.
• Soluble Biotech Protein Formulation Services Protein solubility and stability optimization services using Self Interaction Chromatography combined with neural networks to accelerate drug and vaccine formulation development timelines from approximately one year to 3–4 months.
• Strategic Compute Reserve (Enterprise GPU Infrastructure via Aethir) Enterprise GPU infrastructure service providing access to more than 435,000 GPUs across Aethir's decentralized cloud network for AI workloads, offered via usage-based pricing using ATH tokens.
• STREAMWAY (Automated Medical Fluid Management Device) Automated medical fluid management device product line that directly suctions and disposes of medical fluids for use in operating rooms and surgical environments, operated through Skyline Medical.

Quantifiable outcome

• 92% accuracy in predicting drug-tumor pairings
• +4 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

Eight partnerships are on record, tiered core and flagship.

• Every CurecoreStrategic or Co-development Partner · 1 September 2025Strategic collaboration to pursue drug repurposing for cancer patients using AI-driven analysis to identify new indications for existing drugs. Leverages POAI's biobank and machine learning capabilities.
• AethircoreTechnology or Integration · 1 September 2025Decentralized GPU cloud infrastructure platform partner for the Strategic Compute Reserve. Provides access to over 435,000 GPUs globally. ATH token treasury strategy positions company in AI infrastructure.
• LabcorpcoreChannel Partner/ Reseller/ Distributor · 1 June 2025Developed functional 3D organoid models exclusively for Labcorp. Also partnership for liver toxicity models announced in Q2 2025. Labcorp is a leading global life sciences company.
• FluGencoreStrategic or Co-development Partner · 30 April 2024Collaboration to develop a first-of-its-kind stable intranasal flu vaccine, supported by a $6.2 million Phase 2B grant from the U.S. Department of Defense. Companies are leveraging AI and biologics technology to improve vaccine stability for global distribution, with clinical trials ongoing.
• Integra TherapeuticscoreStrategic or Co-development Partner · 30 March 2023Partnership to pursue novel methods to enhance gene editing capabilities for future cancer therapies. Collaboration focuses on engineering next generation gene writing tools to cure diseases.
• Cancer Research HorizonsflagshipStrategic or Co-development Partner · 17 March 2023Partnership with the world's largest private funder of cancer research to incorporate PEDAL platform into future drug discovery processes. Cancer Research Horizons has 11 marketed drugs, 150+ active licenses, and $647 million revenue from royalties & IP. Enables drug development on global scale.
• CvergenxcoreStrategic or Co-development Partner · 23 February 2023Strategic partnership to create the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence. Combines Predictive Oncology's drug discovery and AI capabilities with Cvergenx's precision genomics radiation therapy platform.
• UPMC Magee-Women's HospitalcoreStrategic or Co-development PartnerMulti-year retrospective ovarian cancer study yielded compelling results leading to company's entry into biomarker discovery market. Demonstrated ability to predict patient outcomes and drug response.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Crown Bioscience: Preclinical oncology services company offering patient-derived xenograft models, 3D tumor models, and drug screening services. Comparable to Predictive Oncology's zPREDICTA 3D tumor models and Soluble Biotech formulation services for pharma/biotech customers.
• Schrödinger: Physics-based computational platform for drug discovery and materials science. Comparable in offering AI/ML-enabled molecular simulation and drug discovery software to pharmaceutical partners, with established enterprise customer base.
• Lantern Pharma: AI-driven oncology drug development company using machine learning to identify and develop cancer therapies. Comparable in applying AI to oncology drug discovery with focus on drug repurposing, smaller-cap peer with similar business model.
• Notable Labs: AI-driven predictive medicine platform testing drug combinations on patient-derived tumor samples to identify effective cancer treatments. Directly comparable to Helomics' ChemoFx drug-response testing service and PEDAL's predictive approach.
• Insitro: Machine learning-driven drug discovery company combining data generation with predictive models. Comparable in using proprietary biological data + AI to accelerate drug development, with strong pharma partnerships (Bristol-Myers Squibb, Eli Lilly).
• Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning to accelerate pharmaceutical R&D. Directly comparable to Predictive Oncology's PEDAL platform in applying ML to compound-target pairings, but at significantly larger scale with multiple pharma partnerships (Roche/Genentech, Bayer).
• Exscientia: AI-native precision medicine company using end-to-end AI-driven drug discovery with patient-derived data. Comparable in applying machine learning to oncology drug discovery and clinical translation, with a similarly strong precision medicine focus.
• Champions Oncology: Patient-derived xenograft (PDX) and tumor model services for oncology drug development. Comparable to Predictive Oncology's zPREDICTA 3D tumor models business, with similar customer base of biopharma companies needing preclinical testing platforms.

Broad incumbents

• Tempus Labs: AI-powered precision medicine company with large-scale molecular and clinical data library for oncology. Overlaps with Predictive Oncology's biomarker discovery and clinical testing services, but operates at significantly larger scale across multiple therapeutic areas.
• Aethir: Decentralized GPU cloud infrastructure network that partnered with Predictive Oncology for the Strategic Compute Reserve. The ecosystem anchor for the company's new GPU infrastructure business line (Axe Compute), providing the underlying infrastructure and ATH token economy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/PredictiveOncology
• LinkedInlinkedin.com/company/precision-therapeutics
• Xx.com/ptincorporated

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries5 records

Funding overview

Funding rounds12 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Predictive Oncology